326 related articles for article (PubMed ID: 36151216)
1. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Hu Y; Zhou Y; Zhang M; Zhao H; Wei G; Ge W; Cui Q; Mu Q; Chen G; Han L; Guo T; Cui J; Jiang X; Zheng X; Yu S; Li X; Zhang X; Chen M; Li X; Gao M; Wang K; Zu C; Zhang H; He X; Wang Y; Wang D; Ren J; Huang H
Cell Res; 2022 Nov; 32(11):995-1007. PubMed ID: 36151216
[TBL] [Abstract][Full Text] [Related]
2. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H
N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244
[TBL] [Abstract][Full Text] [Related]
3. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy.
Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T
Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783
[TBL] [Abstract][Full Text] [Related]
4. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
[TBL] [Abstract][Full Text] [Related]
5. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
6. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
Tan Y; Shan L; Zhao L; Deng B; Ling Z; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Tian Z; Zhang Y; Zhang J; Chang AH; Feng X; Pan J
J Hematol Oncol; 2023 Apr; 16(1):34. PubMed ID: 37020231
[TBL] [Abstract][Full Text] [Related]
8. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.
Zhang Y; Li C; Du M; Jiang H; Luo W; Tang L; Kang Y; Xu J; Wu Z; Wang X; Huang Z; Zhang Y; Wu D; Chang AH; Hu Y; Mei H
Blood Cancer J; 2023 Apr; 13(1):61. PubMed ID: 37095094
[TBL] [Abstract][Full Text] [Related]
9. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
12. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
Song Y; Liu Z; Wang Q; Gao K; Wu T
Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
[TBL] [Abstract][Full Text] [Related]
13. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
14. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
Xie L; Ma L; Liu S; Chang L; Wen F
Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
[TBL] [Abstract][Full Text] [Related]
15. Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.
Li Y; Li Y; Zhang M; Zhao H; Zhu M; Huang H; Hu Y
Eur J Haematol; 2024 Jan; 112(1):94-101. PubMed ID: 37477866
[TBL] [Abstract][Full Text] [Related]
16. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
17. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
Lu P; Liu Y; Yang J; Zhang X; Yang X; Wang H; Wang L; Wang Q; Jin D; Li J; Huang X
Blood; 2022 Jul; 140(4):321-334. PubMed ID: 35500125
[TBL] [Abstract][Full Text] [Related]
18. Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.
Gottlieb DJ; Sutrave G; Jiang W; Avdic S; Street JA; Simms R; Clancy LE; Antonenas V; Gloss BS; Bateman C; Bishop DC; Micklethwaite KP; Blyth E
Am J Hematol; 2023 Jan; 98(1):159-165. PubMed ID: 35560045
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
Chen X; Tan B; Xing H; Zhao X; Ping Y; Zhang Z; Huang J; Shi X; Zhang N; Lin B; Cao W; Li X; Zhang X; Li L; Jiang Z; Zhang M; Li W; Liu M; Du B; Zhang Y
Cancer Immunol Immunother; 2024 Jan; 73(1):13. PubMed ID: 38231412
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.
Yang X; Luo C; Qian J; Huang X; Zhang J; Wang J; Luo C; Qin X; Li B; Chen J
Front Immunol; 2023; 14():1219872. PubMed ID: 37736096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]